Format

Send to

Choose Destination
Semin Immunol. 2017 Dec;34:114-122. doi: 10.1016/j.smim.2017.09.002. Epub 2017 Sep 23.

Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells.

Author information

1
Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, TX 77030, USA; Department of Cell and Developmental Biology, Weill Cornell Medical College, New York, NY 10065, USA.
2
Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, TX 77030, USA.
3
Department of Breast Surgical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
4
Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, TX 77030, USA; Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA. Electronic address: mferrari@HoustonMethodist.org.

Abstract

Cancer immunotherapy has become arguably the most promising advancement in cancer research and therapy in recent years. The efficacy of cancer immunotherapy is critically dependent on specific physiological and physical processes - collectively referred to as transport barriers - including the activation of T cells by antigen presenting cells, T cells migration to and penetration into the tumor microenvironment, and movement of nutrients and other immune cells through the tumor microenvironment. Nanotechnology-based approaches have great potential to help overcome these transport barriers. In this review, we discuss the ways that nanotechnology is being leveraged to improve the efficacy and potency of various cancer immunotherapies.

KEYWORDS:

Cancer immunotherapy; Nanotechnology; Tumor microenvironment; Tumor-infiltrating lymphocytes

PMID:
28947107
PMCID:
PMC5705528
[Available on 2018-12-01]
DOI:
10.1016/j.smim.2017.09.002
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center